Engraftment and outcome after autologous stem cell transplantation in plerixafor-mobilized non-Hodgkin's lymphoma patients

Background Plerixafor is used in combination with granulocyte–colony‐stimulating factor to enhance the mobilization of hematopoietic stem cells. Limited data are available in regard to effects of plerixafor on posttransplant outcomes in chemomobilized patients who appear to mobilize poorly. Study De...

Full description

Saved in:
Bibliographic Details
Published in:Transfusion (Philadelphia, Pa.) Pa.), 2014-05, Vol.54 (5), p.1243-1250
Main Authors: Varmavuo, Ville, Rimpiläinen, Johanna, Kuitunen, Hanne, Nihtinen, Anne, Vasala, Kaija, Mikkola, Maija, Kutila, Anu, Lehtonen, Päivi, Kuittinen, Taru, Mäntymaa, Pentti, Nousiainen, Tapio, Kuittinen, Outi, Jantunen, Esa
Format: Article
Language:English
Subjects:
Adult
Aged
Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy
Antigens, CD34 - analysis
Biological and medical sciences
Blood. Blood and plasma substitutes. Blood products. Blood cells. Blood typing. Plasmapheresis. Apheresis
Cell Separation
Female
Hematologic and hematopoietic diseases
Hematopoietic Stem Cell Mobilization
Hematopoietic Stem Cell Transplantation
Heterocyclic Compounds - pharmacology
Humans
Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis
Lymphoma, Non-Hodgkin - mortality
Lymphoma, Non-Hodgkin - therapy
Male
Medical sciences
Middle Aged
Receptors, CXCR4 - antagonists & inhibitors
Retrospective Studies
Transfusions. Complications. Transfusion reactions. Cell and gene therapy
Transplantation, Autologous
Treatment Outcome
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Plerixafor is used in combination with granulocyte–colony‐stimulating factor to enhance the mobilization of hematopoietic stem cells. Limited data are available in regard to effects of plerixafor on posttransplant outcomes in chemomobilized patients who appear to mobilize poorly. Study Design and Methods Eighty‐nine chemomobilized patients with non‐Hodgkin's lymphoma (NHL) were included in this retrospective study. Thirty‐three patients had received plerixafor preemptively (plerixafor group) and 56 patients served as controls. Posttransplantation outcomes including infections, hematologic recovery, and relapse were recorded. Results The median fold increase of CD34+ cells after the first plerixafor dose was 4.1 in patients mobilized with chemotherapy plus filgrastim and 7.2 in those mobilized with chemotherapy plus pegfilgrastim (p = 0.027). The median number of collected CD34+ cells was 3.5 × 106 CD34+ cells/kg in the plerixafor group and 4.2 × 106 CD34+ cells/kg in the control group (p = 0.076). Early engraftment was comparable between the groups (10 days for neutrophils >0.5 × 109/L and 14 days for platelets >20 × 109/L, respectively). Also late engraftment within 12 months was comparable except higher hemoglobin level at 3 months in the control group (121 g/L vs. 112 g/L, p = 0.009). Progression‐free survival at 1 year after autologous stem cell transplantation (ASCT) was 79% in the plerixafor group and 86% in the control group (p = 0.399). Conclusions Long‐term engraftment and outcome after ASCT seem to be comparable in NHL patients receiving plerixafor compared to chemomobilized patients. These observations support the use of plerixafor in patients who mobilize poorly.
ISSN:0041-1132
1537-2995
DOI:10.1111/trf.12434